These clues collectively implicate that TGF‐β/Smad4 signaling is fundamental for the malignancy of HCC; consequently, the interruption of TGF‐β/Smad4 signaling is a potential antimetastatic therapy for advanced HCC. The gene discussed is SMAD4; the disease is hepatocellular carcinoma.